118 related articles for article (PubMed ID: 17514189)
1. Simple options for improving signal detection in antidepressant clinical trials.
Mallinckrodt CH; Meyers AL; Prakash A; Faries DE; Detke MJ
Psychopharmacol Bull; 2007; 40(2):101-14. PubMed ID: 17514189
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials.
Mallinckrodt CH; Raskin J; Wohlreich MM; Watkin JG; Detke MJ
BMC Psychiatry; 2004 Sep; 4():26. PubMed ID: 15355546
[TBL] [Abstract][Full Text] [Related]
3. Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants.
Mancini M; Wade AG; Perugi G; Lenox-Smith A; Schacht A
J Psychiatr Res; 2014 Apr; 51():21-9. PubMed ID: 24462042
[TBL] [Abstract][Full Text] [Related]
4. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
Nelson JC
Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
6. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
7. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
Iovieno N; Papakostas GI
J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods.
Girardi P; Pompili M; Innamorati M; Mancini M; Serafini G; Mazzarini L; Del Casale A; Tatarelli R; Baldessarini RJ
Hum Psychopharmacol; 2009 Apr; 24(3):177-90. PubMed ID: 19229839
[TBL] [Abstract][Full Text] [Related]
10. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
12. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression.
Howland RH; Wilson MG; Kornstein SG; Clayton AH; Trivedi MH; Wohlreich MM; Fava M
Ann Clin Psychiatry; 2008; 20(4):209-18. PubMed ID: 19034753
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
14. Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials.
Mallinckrodt CH; Tamura RN; Tanaka Y
J Psychiatr Res; 2011 Sep; 45(9):1202-7. PubMed ID: 21453932
[TBL] [Abstract][Full Text] [Related]
15. Factors that influence the outcome of placebo-controlled antidepressant clinical trials.
Niklson IA; Reimitz PE; Sennef C
Psychopharmacol Bull; 1997; 33(1):41-51. PubMed ID: 9133750
[TBL] [Abstract][Full Text] [Related]
16. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
Baldwin DS; Loft H; Dragheim M
Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.
Fraguas R; da Silva Telles RM; Alves TC; Andrei AM; Rays J; Iosifescu DV; Wajngarten M
Contemp Clin Trials; 2009 May; 30(3):205-11. PubMed ID: 19470312
[TBL] [Abstract][Full Text] [Related]
18. Model-based approach and signal detection theory to evaluate the performance of recruitment centers in clinical trials with antidepressant drugs.
Merlo-Pich E; Gomeni R
Clin Pharmacol Ther; 2008 Sep; 84(3):378-84. PubMed ID: 18449185
[TBL] [Abstract][Full Text] [Related]
19. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials.
Gomeni R; Merlo-Pich E
Br J Clin Pharmacol; 2007 May; 63(5):595-613. PubMed ID: 17488364
[TBL] [Abstract][Full Text] [Related]
20. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
Pandina GJ; Revicki DA; Kleinman L; Turkoz I; Wu JH; Kujawa MJ; Mahmoud R; Gharabawi GM
J Affect Disord; 2009 Nov; 118(1-3):139-46. PubMed ID: 19321206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
